Sanofi and Dren Bio have entered into a new agreement to develop therapies for multiple autoimmune diseases, with the deal valued at up to $1.7 billion. Under the terms of the partnership, Dren will receive an upfront payment of $100 million and could earn additional milestone payments based on future progress.
The collaboration will use Dren’s Targeted Myeloid Engager and Phagocytosis Platform to identify multi-specific therapies. Once a development candidate is selected, Sanofi will take responsibility for further development, manufacturing, regulatory activities, and commercialization. Dren retains the option to co-fund future development efforts.
Earlier this year, Sanofi acquired Dren’s DR-0201 program for $600 million upfront, with potential milestone payments totaling $1.3 billion. The program, now named SAR448501, is currently being evaluated in two Phase I clinical trials targeting undisclosed inflammatory conditions.
Dren Bio has also established partnerships with other major pharmaceutical companies. In July 2024, it signed an oncology-focused agreement with Novartis worth up to $3 billion. Additionally, Dren entered into a partnership with Pfizer in 2022 that could exceed $1 billion.
